Aquestive Therapeutics (AQST) Gross Profit (2017 - 2026)

Aquestive Therapeutics' Gross Profit history runs 10 years deep, the most recent figure standing at $13.5 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 165.84% year-over-year to $13.5 million in Q1 2026; TTM through Mar 2026 was $9.8 million, a 81.38% decrease from a year earlier, with the FY2025 full-year figure at -$4.8 million, down 109.21% from the prior year.
• Gross Profit rose to $13.5 million in Q1 2026 per AQST's latest filing, from -$23.6 million in the prior quarter.
• Across five years, Gross Profit topped out at $19.8 million in Q4 2024 and bottomed at -$23.6 million in Q4 2025.
• The 5-year median for Gross Profit is $8.6 million (2025), against an average of $8.0 million.
• Across the five-year window, Gross Profit soared 380.09% in 2023 and sank 219.48% in 2025, its largest moves.
• Year by year, Gross Profit stood at $5.4 million in 2022, then jumped by 43.65% to $7.7 million in 2023, then jumped by 155.83% to $19.8 million in 2024, then sank by 219.48% to -$23.6 million in 2025, then jumped by 157.06% to $13.5 million in 2026.
• Per Business Quant, the three latest AQST Gross Profit figures stand at $13.5 million (Q1 2026), -$23.6 million (Q4 2025), and $11.4 million (Q3 2025).